Lung Cancer

Little research has been done on these complications commonly found in lung cancer.

Researchers focused on a subset of patients with high tumor mutational burden using a 20-mutation-per-megabase threshold and found significant improvement in progression-free survival and overall survival.

Findings from the upcoming International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer show camrelizumab and chemotherapy showed survival benefits for patients with metastatic or otherwise advanced non-squamous non–small-cell lung cancer.

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer.

Researchers tried using deep machine learning to anticipate disease outcomes and progression in patients with lung cancer.

In elderly patients with brain metastasis secondary to small cell lung cancer, whole brain radiation therapy was linked to a modest rise in survival. 

Throughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.

A new study examined whether stereotactic body radiotherapy prior to pembrolizumab improved response rate in lung cancer patients.

A new analysis suggests more people may benefit from more inclusive lung cancer screening guidelines.

Researchers tested the MET inhibitor capmatinib in patients with non–small-cell lung cancer and a MET exon 14 skipping mutation.

Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

The FDA approved pembrolizumab as a treatment option for patients with metastatic small-cell lung cancer.

Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.

Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.

Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.

Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, of Emory University, about talazoparib for patients with HRRD-positive stage IV squamous cell lung cancer.

Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.

Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.

In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.

Cancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC.

In this video, Dr. McFarland of Memorial Sloan-Kettering Cancer Center spoke with Cancer Network at ASCO 2019 about depression in lung cancer and dopamine as potential therapy.

Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope at ASCO 2019 about data on emerging MET inhibitors in the treatment of lung cancer patients.

Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC.

The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non–small-cell lung cancer.

A retrospective study finds that use of checkpoint inhibitors is associated with similar survival outcomes among patients with advanced non–small-cell lung cancer, regardless of a history of autoimmune disorders.

Researchers tested the addition of a pemetrexed-carboplatin chemotherapy regimen to gefitinib for patients with EGFR-mutant advanced non–small-cell lung cancer.